Innovent Biologics has bagged the Chinese rights to three clinical-phase oncology and hematology drugs in growth at Incyte. The agreement sees Innovent pay $40 million upfront and commit to about $350 million in milestones for a trio of drugs which might be in section 2 and 3 testing within the West.
China’s Innovent put itself on the map earlier this yr when it raised $421 million in a Hong Kong IPO. The itemizing, which valued Innovent at round $2 billion, set the biotech up to advance a broad pipeline of clinical-phase drugs and biosimilars—together with the Eli Lilly-partnered anti-PD-1 antibody sintilimab—whereas wanting to add new drugs to the roster.
Now, Innovent has struck a take care of Incyte to add three novel medicines to its pipeline. The most superior of the three candidates is itacitinib, a JAK1 inhibitor Incyte is testing in sufferers with graft-versus-host illness (GvHD). Data from a section 3 trial of itacitinib in acute GvHD are due subsequent yr. Incyte can also be creating itacitinib as a remedy for non-small cell lung most cancers.
A section 3 trial of one other of the drugs licensed by Innovent—FGFR inhibitor pemigatinib—is due to start enrolling sufferers with a type of bile duct most cancers by the tip of the yr. The third asset licensed by Innovent—PI3Kδ inhibitor parsaclisib—is in section 2 growth in non-Hodgkin lymphomas.
While Incyte has targeted on producing the info wanted to crack Western markets, Innovent will take the candidates ahead in China Hong Kong, Macau and Taiwan, the markets coated by the deal. Innovent plans to file the primary IND for the drugs in China subsequent yr, at which level it’ll pay Incyte a $20 million milestone.
The Chinese medical growth packages will present a take a look at of Innovent’s pitch to Western drug builders. Having constructed up infrastructure to help the event and commercialization of sintilimab and biosimilar copies of Avastin, Humira and MabThera, Innovent thinks it has the assets to take drugs from Western corporations and produce them to Chinese sufferers.
“[We believe] this collaboration … proves that Innovent is an ideal partner for world-class pharmaceutical companies coming to China—transforming Innovent from a company primarily focused on monoclonal antibodies to one with a broader oncology focus that develops potentially innovative treatments regardless of molecule size,” Innovent CEO Michael Yu stated in a press release.